<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637076</url>
  </required_header>
  <id_info>
    <org_study_id>017-2014</org_study_id>
    <nct_id>NCT02637076</nct_id>
  </id_info>
  <brief_title>Xyrem and Brain Dopamine in Narcolepsy</brief_title>
  <official_title>Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this investigation is to establish whether an action of Xyrem速 on the&#xD;
      brain dopamine system in patients with narcolepsy, and in a comparison control group, might&#xD;
      explain part of the anti-narcoleptic effect of the drug.&#xD;
&#xD;
      Trial Objective is to establish, using positron emission tomography (PET), in Xyrem速-na誰ve&#xD;
      narcolepsy with cataplexy patients, and in matched controls, whether a single dose of Xyrem速&#xD;
      causes changes in striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered&#xD;
      activity of brain dopamine neurones.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be recruited to fill 2 separate study groups: 1) participants with a diagnosis of narcolepsy with cataplexy; 2) healthy controls.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[C-11]Raclopride BPND at 1 Hour Post Xyrem</measure>
    <time_frame>1 hour post Xyrem</time_frame>
    <description>BPND (Binding Potential) of [C-11]raclopride measures 1 hour after taking a single 3g dose of Xyrem.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</measure>
    <time_frame>1 hour post Xyrem</time_frame>
    <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[C-11]Raclopride BPND at 7 Hours Post Xyrem</measure>
    <time_frame>7 hours post Xyrem</time_frame>
    <description>BPND (Binding Potential) of [C-11]raclopride measures 7 hours after taking a single 3g dose of Xyrem.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</measure>
    <time_frame>7 hours post Xyrem</time_frame>
    <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>[C-11]DTBZ BPND at 5 Hours Post Xyrem</measure>
    <time_frame>5 hours post single Xyrem dose</time_frame>
    <description>Measurement of [C-11]DTBZ 5 hours after taking a single dose of 3g Xyrem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem</measure>
    <time_frame>5 hours post single Xyrem dose</time_frame>
    <description>[C-11] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)</measure>
    <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
    <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Gamma-hydroxybutyrate (GHB) Cmax</measure>
    <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
    <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Drowsiness</measure>
    <time_frame>observed after receiving single dose of Xyrem, up to 9 hours</time_frame>
    <description>Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Narcolepsy With Cataplexy</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients given single dose of Xyrem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy controls given a single dose of Xyrem</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xyrem</intervention_name>
    <description>single 3.0 gram dose</description>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>narcolepsy with cataplexy</arm_group_label>
    <other_name>Sodium Oxybate</other_name>
    <other_name>gamma-hydroxybutyrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  current diagnosis of narcolepsy with cataplexy OR healthy control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except&#xD;
             non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine&#xD;
             at start of baseline period&#xD;
&#xD;
          -  significant unstable or uncontrolled medical/psychiatric disease&#xD;
&#xD;
          -  significant history of head trauma/surgery or seizure disorder&#xD;
&#xD;
          -  radiation exposure exceeding 20mSv in last 12 months&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  substance abuse/dependence (including alcohol)&#xD;
&#xD;
          -  have sleep apnea, or are shift workers&#xD;
&#xD;
          -  on a sodium-restricted diet&#xD;
&#xD;
          -  has ever taken Xyrem / sodium oxybate / GHB at any time&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  metal implants / objects in the body that may interfere with MRI&#xD;
&#xD;
          -  succinic semialdehyde dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Kish, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>February 2, 2021</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2021</results_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Stephen Kish</investigator_full_name>
    <investigator_title>Senior Scientist, Head Human Brain Lab</investigator_title>
  </responsible_party>
  <keyword>Xyrem</keyword>
  <keyword>narcolepsy with cataplexy</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Cataplexy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02637076/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02637076/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Narcolepsy With Cataplexy</title>
          <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>due to technical difficulties, the 1 hour post PET scan was not completed at the one hour time point</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Narcolepsy With Cataplexy</title>
          <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="29.6" spread="8"/>
                    <measurement group_id="B3" value="31.6" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>[C-11]raclopride BPND at Baseline</title>
          <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.</description>
          <units>BPND (Binding Potential)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.59"/>
                    <measurement group_id="B2" value="2.83" spread="0.19"/>
                    <measurement group_id="B3" value="2.80" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.06"/>
                    <measurement group_id="B2" value="3.63" spread="0.32"/>
                    <measurement group_id="B3" value="3.58" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.11"/>
                    <measurement group_id="B2" value="4.04" spread="0.43"/>
                    <measurement group_id="B3" value="3.96" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>[C-11]DTBZ BPND at Baseline</title>
          <description>[C-11] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy.</description>
          <units>BPND (Binding Potential)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.68"/>
                    <measurement group_id="B2" value="1.85" spread="0.19"/>
                    <measurement group_id="B3" value="1.84" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.41"/>
                    <measurement group_id="B2" value="2.60" spread="0.26"/>
                    <measurement group_id="B3" value="2.58" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.49"/>
                    <measurement group_id="B2" value="3.05" spread="0.38"/>
                    <measurement group_id="B3" value="3.00" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>[C-11]Raclopride BPND at 1 Hour Post Xyrem</title>
        <description>BPND (Binding Potential) of [C-11]raclopride measures 1 hour after taking a single 3g dose of Xyrem.</description>
        <time_frame>1 hour post Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>[C-11]Raclopride BPND at 1 Hour Post Xyrem</title>
          <description>BPND (Binding Potential) of [C-11]raclopride measures 1 hour after taking a single 3g dose of Xyrem.</description>
          <units>BPND (Binding Potential)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94"/>
                    <measurement group_id="O2" value="3.01" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associate Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80"/>
                    <measurement group_id="O2" value="3.70" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87"/>
                    <measurement group_id="O2" value="4.11" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>repeated measures ANOVA</method>
            <method_desc>F(2,36)=1.26</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</title>
        <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
        <time_frame>1 hour post Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</title>
          <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (1 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Stiatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.27"/>
                    <measurement group_id="O2" value="6.49" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.88"/>
                    <measurement group_id="O2" value="2.11" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.43"/>
                    <measurement group_id="O2" value="1.93" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>[C-11]Raclopride BPND at 7 Hours Post Xyrem</title>
        <description>BPND (Binding Potential) of [C-11]raclopride measures 7 hours after taking a single 3g dose of Xyrem.</description>
        <time_frame>7 hours post Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>[C-11]Raclopride BPND at 7 Hours Post Xyrem</title>
          <description>BPND (Binding Potential) of [C-11]raclopride measures 7 hours after taking a single 3g dose of Xyrem.</description>
          <units>BPND (Binding Potential)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33"/>
                    <measurement group_id="O2" value="2.76" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associate Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83"/>
                    <measurement group_id="O2" value="3.62" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75"/>
                    <measurement group_id="O2" value="4.06" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</title>
        <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
        <time_frame>7 hours post Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>% Change in PET [C11]Raclopride Binding From Baseline After Single Dose of Xyrem</title>
          <description>[C-11] raclopride is a radioligand that binds to the D2/3 dopamine receptor in the dopamine-rich striatum and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (7 hours BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.13"/>
                    <measurement group_id="O2" value="-2.07" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50"/>
                    <measurement group_id="O2" value="0.17" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.56"/>
                    <measurement group_id="O2" value="0.72" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>[C-11]DTBZ BPND at 5 Hours Post Xyrem</title>
        <description>Measurement of [C-11]DTBZ 5 hours after taking a single dose of 3g Xyrem</description>
        <time_frame>5 hours post single Xyrem dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>[C-11]DTBZ BPND at 5 Hours Post Xyrem</title>
          <description>Measurement of [C-11]DTBZ 5 hours after taking a single dose of 3g Xyrem</description>
          <units>BPND (binding potential)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71"/>
                    <measurement group_id="O2" value="1.82" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56"/>
                    <measurement group_id="O2" value="2.65" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65"/>
                    <measurement group_id="O2" value="3.12" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem</title>
        <description>[C-11] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
        <time_frame>5 hours post single Xyrem dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>% Change in PET [C-11] Dihydrotetrabenazine (DTBZ) Binding From Baseline to Five Hours Post Xyrem</title>
          <description>[C-11] DTBZ is a radioligand that binds to the vesicular monoamine transporter and which is sensitive to dopamine occupancy.&#xD;
% change was calculated as follows: (5 hour BPND - baseline BPND)/baseline BPND *100; Mean % change represents the mean of each participant's individual % change within the group.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Limbic Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00"/>
                    <measurement group_id="O2" value="-1.98" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associative Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10"/>
                    <measurement group_id="O2" value="2.04" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensorimotor Striatum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.51"/>
                    <measurement group_id="O2" value="2.47" spread="12.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.748</p_value>
            <method>repeated measures ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)</title>
        <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.</description>
        <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gamma-hydroxybutyrate (GHB) Concentration (AUC)</title>
          <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem, as measured by Area Under the Curve.</description>
          <units>AUC (ug/ml*hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.03"/>
                    <measurement group_id="O2" value="178.49" spread="52.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Gamma-hydroxybutyrate (GHB) Cmax</title>
        <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.</description>
        <time_frame>multiple time points from 0 to 7 hours post-Xyrem</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Gamma-hydroxybutyrate (GHB) Cmax</title>
          <description>The concentration of gammahydroxybutyrate in blood of participants who have received a single dose of Xyrem as measured by Cmax.</description>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="107.37" spread="32.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Drowsiness</title>
        <description>Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.</description>
        <time_frame>observed after receiving single dose of Xyrem, up to 9 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Narcolepsy With Cataplexy</title>
            <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Drowsiness</title>
          <description>Period of time when the participant was experiencing the sedative action of Xyrem. Data derived from self-report as well as anesthesiologist observation.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.20"/>
                    <measurement group_id="O2" value="92.4" lower_limit="10.02" upper_limit="285.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be assessed at each study visit following administration of the first PET radiotracer until the follow-up phone after Xyrem administration (2 visits plus 1 follow-up phone call), an average of 10 days per participant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Narcolepsy With Cataplexy</title>
          <description>patients given single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>healthy controls given a single dose of Xyrem&#xD;
Xyrem: single 3.0 gram dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen Kish</name_or_title>
      <organization>CAMH</organization>
      <phone>416-535-8501 ext 36256</phone>
      <email>stephen.kish@utoronto.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

